Sanofi-Aventis Asia Pacific R&D Head Frank Jiang On Opportunities In China And India: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Sanofi-Aventis VPand Head, Asia PacificR&D Frank Jiang talked to PharmAsia News along the sidelines of the recent DIA China conference in Beijing. Jiang shared his vision of how the company is revamping its R&D strategies in Asia to bring more therapies to patients in India and China.
You may also be interested in...
Quick Take: AstraZeneca Pursues Traditional Chinese Medicine As New Source For R&D
AstraZeneca signs research collaboration with Shanghai’s Fudan University to investigate mechanism of action for a TCM compound to treat cardiovascular disease.
GSK Establishes Discovery Unit For Traditional Chinese Medicine
GSK transforms DPU in Shanghai into TCM discovery unit that will consist of a small number of select scientists with both Western drug discovery experience and TCM knowledge.
Traditional Chinese Medicines Seen As Global Growth Opportunity
HONG KONG - Health authorities around the world are working to develop regulatory structures for traditional Chinese medicines